EA201290797A1 - СПОСОБ ПОЛУЧЕНИЯ АДЕНОВИРУСНЫХ ВЕКТОРОВ Ad26 - Google Patents
СПОСОБ ПОЛУЧЕНИЯ АДЕНОВИРУСНЫХ ВЕКТОРОВ Ad26Info
- Publication number
- EA201290797A1 EA201290797A1 EA201290797A EA201290797A EA201290797A1 EA 201290797 A1 EA201290797 A1 EA 201290797A1 EA 201290797 A EA201290797 A EA 201290797A EA 201290797 A EA201290797 A EA 201290797A EA 201290797 A1 EA201290797 A1 EA 201290797A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- adrioviral
- vectors
- obtaining
- infection
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение относится к способам крупномасштабного продуцирования рекомбинантного аденовируса 26 с использованием перфузионных систем и инфицирования при очень высокой клеточной плотности.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30455310P | 2010-02-15 | 2010-02-15 | |
EP10153581 | 2010-02-15 | ||
PCT/EP2011/052109 WO2011098592A1 (en) | 2010-02-15 | 2011-02-14 | Method for the production of ad26 adenoviral vectors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201290797A1 true EA201290797A1 (ru) | 2013-01-30 |
EA023816B1 EA023816B1 (ru) | 2016-07-29 |
Family
ID=42227128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201290797A EA023816B1 (ru) | 2010-02-15 | 2011-02-14 | СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2536829B1 (ru) |
JP (1) | JP5250155B2 (ru) |
KR (1) | KR101820980B1 (ru) |
CN (1) | CN102762721B (ru) |
AU (1) | AU2011214262B2 (ru) |
BR (1) | BR112012019023B1 (ru) |
CA (1) | CA2786835C (ru) |
DK (1) | DK2536829T3 (ru) |
EA (1) | EA023816B1 (ru) |
ES (1) | ES2578514T3 (ru) |
MX (1) | MX2012007936A (ru) |
NZ (1) | NZ601424A (ru) |
PL (1) | PL2536829T3 (ru) |
WO (1) | WO2011098592A1 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2350268T3 (pl) | 2008-11-03 | 2015-05-29 | Crucell Holland Bv | Sposób wytwarzania wektorów adenowirusowych |
AU2011310838B2 (en) | 2010-09-27 | 2015-11-05 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
WO2013074501A1 (en) | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
CN103305417A (zh) * | 2012-03-07 | 2013-09-18 | 无锡药明康德生物技术有限公司 | 进行蛋白生产的高产量反应器及其生产方法和应用 |
EA034284B1 (ru) | 2012-03-12 | 2020-01-24 | Янссен Вэксинс Энд Превеншн Б.В. | Частицы рекомбинантного трансгенсодержащего аденовируса с 5'-концевыми нуклеотидами ctatctat |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
EP2827894B1 (en) | 2012-03-22 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
WO2014202570A1 (en) | 2013-06-17 | 2014-12-24 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
EP3613841B1 (en) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Passive replacement of media |
AP2017009846A0 (en) * | 2014-09-26 | 2017-03-31 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
NZ730802A (en) | 2014-11-04 | 2021-12-24 | Janssen Vaccines & Prevention Bv | Therapeutic hpv16 vaccines |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
CA2991540A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides |
BR112017027448A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
JP6470872B2 (ja) | 2015-08-20 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 治療用hpv18ワクチン |
US11155583B2 (en) | 2016-04-05 | 2021-10-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
MA43762A (fr) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Vaccin contre le rsv |
BR112018072372A2 (pt) | 2016-05-02 | 2019-02-19 | Janssen Vaccines & Prevention B.V. | combinações de vacina terapêutica contra o hpv |
WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
CA3025441A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
JP7272965B2 (ja) | 2017-06-15 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hiv抗原をコードするポックスウイルスベクターおよびその使用方法 |
MX2020002876A (es) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention Bv | Metodo para la induccion segura de inmunidad contra el vsr. |
JP7438943B2 (ja) | 2017-10-31 | 2024-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルス及びその用途 |
SG11202003290RA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
SG11202003398SA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof |
KR20200077559A (ko) | 2017-10-31 | 2020-06-30 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 및 이의 용도 |
TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗 |
MX2023011629A (es) | 2021-04-01 | 2023-10-13 | Janssen Vaccines & Prevention Bv | Proteinas piv3 f prefusion estabilizadas. |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
WO2024061753A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US6686200B1 (en) * | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
ES2333425T5 (es) | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
EP0847442A1 (en) | 1995-08-30 | 1998-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
BR9713368A (pt) | 1996-11-20 | 2001-09-18 | Introgen Therapeutics Inc | Processo melhorado para a produção e a purificação de vetores adenovirais |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
JP2000509614A (ja) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | アデノウイルスe1−相補性細胞系 |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
TWI232107B (en) | 1998-02-17 | 2005-05-11 | Schering Corp | Compositions comprising viruses and methods for concentrating virus preparations |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
WO1999054441A1 (en) | 1998-04-22 | 1999-10-28 | Genvec, Inc. | Efficient purification of adenovirus |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1977764A1 (en) | 1998-11-16 | 2008-10-08 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
JP2003523169A (ja) | 1998-12-31 | 2003-08-05 | アバンテイス・フアルマ・エス・アー | ウイルス粒子の分離法 |
ATE332364T1 (de) | 1999-02-22 | 2006-07-15 | Transgene Sa | Verfahren zur gewinnung von purifizierter virenzuammensetzung |
PT1550722E (pt) * | 1999-05-17 | 2007-09-25 | Crucell Holland Bv | ''adenovírus humano recombinante do serótipo 35'' |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
AU4346101A (en) | 2000-03-07 | 2001-09-17 | Merck & Co., Inc. | Adenovirus formulations |
US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
WO2003049764A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for viral preservation |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
EP1497438B1 (en) | 2002-04-25 | 2009-10-28 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
ES2285120T3 (es) | 2002-05-14 | 2007-11-16 | MERCK & CO., INC. | Procedimientos de purificacion de adenovirus. |
EP2258850B1 (en) * | 2002-12-17 | 2013-07-17 | Crucell Holland B.V. | Recominant viral-based malaria vaccins |
EP1718738A2 (en) | 2004-02-23 | 2006-11-08 | Crucell Holland B.V. | Virus purification methods |
US8206981B2 (en) * | 2004-03-05 | 2012-06-26 | Dsm Ip Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
BRPI0518933A2 (pt) | 2004-11-16 | 2008-12-16 | Crucell Holland B V E Aeras Gl | adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium |
EP1851343A2 (en) * | 2005-02-11 | 2007-11-07 | Merck and Co., Inc. | Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby |
CN101155915B (zh) | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
US20100143302A1 (en) * | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
PL2350268T3 (pl) * | 2008-11-03 | 2015-05-29 | Crucell Holland Bv | Sposób wytwarzania wektorów adenowirusowych |
-
2011
- 2011-02-14 EP EP11703221.9A patent/EP2536829B1/en active Active
- 2011-02-14 AU AU2011214262A patent/AU2011214262B2/en active Active
- 2011-02-14 ES ES11703221.9T patent/ES2578514T3/es active Active
- 2011-02-14 MX MX2012007936A patent/MX2012007936A/es active IP Right Grant
- 2011-02-14 NZ NZ601424A patent/NZ601424A/en not_active IP Right Cessation
- 2011-02-14 DK DK11703221.9T patent/DK2536829T3/en active
- 2011-02-14 WO PCT/EP2011/052109 patent/WO2011098592A1/en active Application Filing
- 2011-02-14 EA EA201290797A patent/EA023816B1/ru not_active IP Right Cessation
- 2011-02-14 BR BR112012019023-7A patent/BR112012019023B1/pt active IP Right Grant
- 2011-02-14 KR KR1020127022501A patent/KR101820980B1/ko active IP Right Grant
- 2011-02-14 JP JP2012552419A patent/JP5250155B2/ja active Active
- 2011-02-14 CA CA2786835A patent/CA2786835C/en active Active
- 2011-02-14 PL PL11703221.9T patent/PL2536829T3/pl unknown
- 2011-02-14 CN CN201180009594.7A patent/CN102762721B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
DK2536829T3 (en) | 2016-07-04 |
WO2011098592A1 (en) | 2011-08-18 |
PL2536829T3 (pl) | 2016-09-30 |
ES2578514T3 (es) | 2016-07-27 |
CA2786835A1 (en) | 2011-08-18 |
JP2013519366A (ja) | 2013-05-30 |
KR101820980B1 (ko) | 2018-01-22 |
EA023816B1 (ru) | 2016-07-29 |
EP2536829B1 (en) | 2016-04-06 |
CA2786835C (en) | 2021-08-31 |
EP2536829A1 (en) | 2012-12-26 |
KR20130026518A (ko) | 2013-03-13 |
NZ601424A (en) | 2014-07-25 |
JP5250155B2 (ja) | 2013-07-31 |
BR112012019023B1 (pt) | 2021-12-21 |
CN102762721A (zh) | 2012-10-31 |
AU2011214262B2 (en) | 2015-05-21 |
MX2012007936A (es) | 2012-11-22 |
BR112012019023A2 (pt) | 2015-09-15 |
AU2011214262A1 (en) | 2012-08-30 |
CN102762721B (zh) | 2015-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201290797A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ АДЕНОВИРУСНЫХ ВЕКТОРОВ Ad26 | |
EA201170638A1 (ru) | Способ получения аденовирусных векторов | |
CL2016001190A1 (es) | Cultivo de células de mamífero. | |
EA201171018A1 (ru) | Биореактор для культивирования клеток млекопитающих | |
UY34352A (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
DK3064508T4 (da) | Fremgangsmåde til fremstilling af rekombinant vwf med høj molekylevægt i cellekultur | |
UY34365A (es) | Compuestos heterociclicos | |
DK2697185T3 (da) | Fremgangsmåder til fremstilling af biogene reagenser med højt kulstofindhold | |
EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
UY34374A (es) | Benzilindazoles sustituidos | |
BR112013017632A2 (pt) | meio de cultura celular | |
EA201391254A1 (ru) | Способ получения агонистов гуанилатциклазы c | |
UY34227A (es) | Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo | |
MX2018014043A (es) | Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos. | |
WO2012068317A3 (en) | Methods for producing recombinant proteins | |
EA201201645A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ F-18 МЕЧЕННЫХ Аβ-ЛИГАНДОВ | |
UA111827C2 (uk) | Спосіб отримання інгенол-3-ангелату | |
DK3036320T3 (da) | Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre | |
BR112015021189A2 (pt) | métodos de banco de células de alta densidade | |
BR112013014457A2 (pt) | método com base em mgmt para obter alta produção de expressão de proteína recombinante | |
MX2015011781A (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
DK2825633T3 (da) | Fremgangsmåde til dyrkning af E. coli-celler til høj densitet | |
DK3342867T3 (da) | Xylanasemutant, fremgangsmåde til fremstilling og anvendelse herfor, og fremgangsmåde til fremstilling af forsukret lignocellulose | |
SG10201806083RA (en) | Microcarrier perfusion culturing methods and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |